United Kingdom

People: Bellerophon Therapeutics Inc (BLPH.OQ)

BLPH.OQ on NASDAQ Stock Exchange Global Market

23 Aug 2019
Change (% chg)

$-0.04 (-5.74%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Meglasson, Martin 

Dr. Martin D. Meglasson, Ph.D., is Chief Scientific Officer, Vice President of Bellerophon Therapeutics LLC, since February 2014. From July 2010 to February 2014, Dr. Meglasson served as Chief Scientific Officer of Ikaria. Prior to joining Ikaria, Dr. Meglasson served as Vice President, head of Research and Development of Ligand Pharmaceuticals Incorporated, a biotechnology company, from February 2004 to July 2010. From 1996 to 2003, Dr. Meglasson was Director of Preclinical Pharmacology at Pharmacia, Inc., a pharmaceutical company, and from 1984 to 1992, he was first an Assistant Professor and later an Associate Professor of Pharmacology at the University of Pennsylvania School of Medicine. Dr. Meglasson received a B.S. in biology, an M.S. in physiology and a Ph.D. in pharmacology, each from the University of Houston.

Basic Compensation

Total Annual Compensation, USD 573,314
Restricted Stock Award, USD --
Long-Term Incentive Plans, USD --
All Other, USD 79,246
Fiscal Year Total, USD 652,560

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --